ALV
0.047
104.3%
WLD
0.014
-51.7%
SRN
0.002
100%
MEL
0.001
-50%
MML
0.034
54.5%
QFE
0.067
-46.4%
C7A
0.003
50%
JNS
0.099
-41.8%
IRX
0.036
38.5%
SFX
0.072
-34.5%
1AI
0.012
33.3%
DRO
1.715
-34%
FRS
0.265
32.5%
CHM
0.002
-33.3%
ROC
0.165
32%
TEM
0.007
-30%
RAS
0.038
31%
ECS
0.005
-28.6%
ECL
4.31
30.6%
USL
0.49
-27.4%
CXU
0.022
29.4%
IFG
0.008
-27.3%
MRD
0.033
26.9%
RNV
0.115
-25.8%
GW1
0.038
26.7%
AI1
0.057
-25%
STM
0.024
26.3%
BIT
0.003
-25%
PMT
0.505
26.3%
KRR
0.012
-25%
BPM
0.17
25.9%
SPX
0.003
-25%
RKB
0.005
25%
ASN
0.079
-24.8%
TGN
0.155
24%
C29
0.019
-24%
GT1
0.037
23.3%
SVY
0.013
-23.5%
A11
0.22
22.2%
NC1
0.1
-23.1%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

CMH Clinical trial openfor enrollment

Chimeric Therapeutics (ASX:CHM), Australian leader in cell therapy, announces the Phase 18 ADVENT-AML clinical trial for patients with newly diagnosed Acute Myeloid Leukaemia is now open to enrolment at The University of Texas MD Anderson Cancer Center https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02762504-2A1499759